	Edgar Filing: CLEVEL	AND BIOLABS INC	C - Form 3
CLEVELAND BIOLABS INC	C		
Form 3			
July 28, 2016			
			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per 0.5 response...

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> SALUCK RANDY S.			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol CLEVELAND BIOLABS INC [CBLI]					
(Last) (F	First)	(Middle)	07/21/2016	4. Relationshi Person(s) to Is	p of Reporting	5. If Amendment, Date Original Filed(Month/Day/Year)			
C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET				(Check all applicable)					
(S	street)			X_Director10% Owner OfficerOther (give title below) (specify below)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting		
BUFFALO, NY 14203						Person Form filed by More than One Reporting Person			
(City) (S	State)	(Zip)	Table I - I	neficially Owned					
1.Title of Security (Instr. 4)			2. Amount of Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	*		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)									
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.									
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I)	

### Edgar Filing: CLEVELAND BIOLABS INC - Form 3

						(Instr. 5)	
Stock Option (right to buy)	(1)	04/22/2025	Common Stock	16,000	\$ 3.2	D	Â
Stock Option (right to buy)	(1)	06/11/2024	Common Stock	1,750	\$ 9.8	D	Â
Stock Option (right to buy)	(1)	04/19/2023	Common Stock	750	\$ 36.4	D	Â
Stock Option (right to buy)	(1)	06/14/2023	Common Stock	1,750	\$ 31.6	D	Â
Common Stock Warrants (right to buy)	(1)	10/24/2017	Common Stock	1,250	\$ 60	Ι	Held by Mortar Rock, L.P. $(2)$

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
SALUCK RANDY S. C/O CLEVELAND BIOLABS, INC. 73 HIGH STREET BUFFALO, NY 14203	ÂX	Â	Â	Â		
Signatures						
/s/ C. Neil Lyons, Attorney-in-fact for Saluck	0	7/28/20	16			

**Signature of Reporting Person Date

### **Explanation of Responses:**

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The holder of this security may exercise it at any time.
- (2) Mr. Saluck is a managing member of Mortar Rock Capital Management, LLC, which manages Mortar Rock, L.P.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.